Streetwise Live! Presents Vox Royalty Corp. (VOX:TSX.V) on 03/12/2021. Learn More

Streetwise Reports' Article Archives — December 2020 back to current month (29)

California Biotech Advances Two COVID-19 Products (12/30/2020)

Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report.

more>

Biotech On Track for Trio of Drugs in Clinical Trials in 2021 (12/30/2020)

The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report.

more>

DermTech Shares Rise 32% on Geisinger Health Support for Skin Cancer Test (12/30/2020)

Shares of DermTech Inc. climbed to a new 52-week high after the company reported it has received positive medical coverage by Geisinger Health System for its pigmented lesion assay, a non-invasive test for detecting melanoma.

more>

Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review (12/29/2020)

Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication.

more>

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer (12/28/2020)

Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada.

more>

Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy (12/23/2020)

The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report.

more>

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher (12/23/2020)

Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder.

more>

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program (12/22/2020)

Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program.

more>

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study (12/21/2020)

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.

more>

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties (12/21/2020)

Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties.

more>

Life Sciences Firm Reports Year of Record Breaking Orders (12/18/2020)

Avivagen Inc. reported FY/20 audited financial results that included a 20.5% increase in YoY revenue.

more>

BioTelemetry Shares Beat Higher on Royal Philips $2.8 Billion Buyout Offer (12/18/2020)

Shares of BioTelemetry Inc. rise 16.5% to a new 52-week high after Royal Philips agreed to acquire the company for US$2.8 billion, or US$72.00 per share in an all cash transaction.

more>

Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment (12/17/2020)

Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme.

more>

Why XPhyto's PCR Test Kit Is a Game Changer for COVID-19 Testing (12/17/2020)

Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes.

more>

US Specialty Pharma Makes 'Another Acquisition to Bolster Topline' (12/16/2020)

The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report.

more>

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends' (12/16/2020)

Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report.

more>

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial (12/16/2020)

Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.

more>

Eli Lilly's $1.04 Billion Buyout Offer Sends Prevail Therapeutics' Shares 82% Higher (12/15/2020)

Shares of Prevail Therapeutics reached a new 52-week high after the company reported it has signed a definitive agreement to be acquired by Ely Lilly in a deal valued up to $1.04 billion.

more>

Alexion Pharma Shares Jump 30% on AstraZeneca's $39 Billion Buyout Offer (12/14/2020)

Shares of Alexion Pharmaceuticals reached a new 52-week high after the company reported it entered into a definitive agreement to be acquired by AstraZeneca in a combination cash and stock deal valued at US$39 billion.

more>

NantHealth's Shares Gain 35% after Presenting Breast Cancer Treatment Insights to Texas Conference (12/11/2020)

Shares of NantHealth Inc. climbed to a new 52-week high after the healthcare IT company presented what it called significant treatment insights at the 2020 San Antonio Breast Cancer Symposium.

more>

TG Therapeutics Shares Rise 40% on Positive Topline Data from Two Phase 3 RMS Trials (12/10/2020)

Shares of TG Therapeutics reached a new 52-week high after the company released positive topline results from the Phase 3 ULTIMATE I & II Studies of ublituximab as a monotherapy for treating relapsing multiple sclerosis.

more>

Grenwich Shares Skyrocket 2,300% After Firm Presents 5-Year Clinical Breast Cancer Trial Data Showing 0% Recurrence (12/09/2020)

Shares of Grenwich Lifesciences soared more than 2,300% to a new 52-week high after the company gave a poster presentation of 5-year data for the Phase 2b GP2 clinical trial that showed 0% recurrence of breast cancer.

more>

Curis Shares Soar 300% on Positive Data from Two Ongoing Phase 1 Cancer Studies (12/08/2020)

Curis Inc. shares reached a new 52-week high after the cancer therapeutics developer reported positive preliminary data from two Phase 1 studies, one treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes and another treating relapsed or refractory non-Hodgkin's lymphoma.

more>

Fate Therapeutics Shares Twist 37% Upward on Data from Two Phase 1 B-cell Lymphoma Trials (12/07/2020)

Fate Therapeutics shares set a new 52-week high after the firm reported positive interim data from its Phase 1 Study of FT516 in combination with rituximab for B-cell lymphoma. In a separate Phase 1 study, the company presented the results of a patient treated with natural killer cell cancer immunotherapy FT596 in refractory diffuse large B-cell lymphoma.

more>

Biotech's Potentially Disruptive Diagnostics Platform on 'Cusp of Commercialization' (12/06/2020)

Recent trial results, a timeline to the launch of Quotient's system and the reasons the debut should be successful are discussed in a Cowen report.

more>

BioCryst Awarded FDA Approval for Medicine Preventing Attacks in HAE Patients (12/04/2020)

BioCryst Pharmaceuticals shares traded 17% higher after the company reported that the FDA approved its once-daily oral therapy ORLADEYO™ (berotralstat) for prevention of attacks in hereditary angioedema patients.

more>

Oramed Pharma Shares Gain 11% as Firm Initiates Phase 2 NASH Trial of Oral Insulin (12/03/2020)

Shares of Oramed Pharmaceuticals traded higher after the company announced that it has initiated a Phase 2 NASH trial of oral insulin as a complementary agent or alternative to insulin injections.

more>

Biotech Licenses Platform for Faster Pathway for Cancer and COVID-19 Vaccine Trials (12/02/2020)

The rationale behind OncoSec Medical using this system is discussed in a Dawson James report.

more>

Patterson Company's Shares Gain 13% on Q2 Earnings and 9.5% YoY Sales Growth (12/02/2020)

Patterson Companies shares traded higher and set a new 52-week high after the firm reported Q2/21 financial results which included a 12.1% YoY increase in dental equipment and consumable supply sales.

more>

More Archives

2021Feb Jan

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes